Prevalence of cholinesterase inhibitors in subjects with dementia in Europe

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 7, 2008, Pages 655-660

  Pariente, Antoine ^a,b,c   Helmer, Catherine ^d   Merliere, Yvon ^e   Moore, Nicholas ^a,b,c   Fourrier Réglat, Annie ^a,b,c   Dartigues, Jean Francois ^a,b,c  

^a INSERM U657   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSERM   (France)

^e Bioinformatique et Chimie Moléculaire   (France)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Dementia; Drug therapy; Prevalence

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ARTICLE; BELGIUM; CLINICAL PRACTICE; DEMENTIA; DRUG USE; EVALUATION RESEARCH; FRANCE; GERMANY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; ITALY; NETHERLANDS; POLAND; POPULATION RESEARCH; PORTUGAL; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; SPAIN; UNITED KINGDOM;

EID: 48249105116     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1613     Document Type: Article

References (18)

1. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br Med J 2005; 331(7512): 321-327.
2. Frisoni GB. Reimbursement of acetilcholinesterase inhibitors for Alzheimer's disease in Europe. Int J Geriatr Psychiatry 2001; 16(2): 233-235.
3. Oude Voshaar RC, Burns A, Olde Rikkert MG. Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int J Geriatr Psychiatry 2006; 21(1): 29-31.
4. Bond J, Stave C, Sganga A, O'Connell B, Stanley RL. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract Suppl 2005(146): 8-14.
5. Bush C, Kozak J, Elmslie T. Screening for cognitive impairment in the elderly. Can Fam Physician 1997; 43: 1763-1768.
6. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 1995; 122(6): 422-429.
7. Lopponen M, Raiha I, Isoaho R, Vahlberg T, Kivela SL. Diagnosing cognitive impairment and dementia in primary health care - a more active approach is needed. Age Ageing 2003; 32(6): 606-612.
8. O'Connor DW, Pollitt PA, Hyde JB, Brook CP, Reiss BB, Roth M. Do general practitioners miss dementia in elderly patients? Br Med J 1988; 297(6656): 1107-1110.
9. Olafsdottir M, Skoog I, Marcusson J. Detection of dementia in primary care: the Linkoping study. Dement Geriatr Cogn Disord 2000; 11(4): 223-229.
10. Vantelon C, Gilbert S, Kerneis S, Wolmark Y, Legrain S, Kergoat MJ. Cholinesterase inhibitor therapy in long term care settings. Rev Med Interne 2006; 27(8): 588-594.
11. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54(11 Suppl 5): S4-9.
12. United States Census Bureau. U. S. Census International Database 2007 [cited 2007 2007/03/23]; Available from: http://www.census.gov/ipc/www/ idbnew.html
13. Day M. NICE says anti-dementia drugs should be used only for moderate Alzbeimer's disease. Br Med J 2006; 333(7572): 774.
14. Bellelli G, Lucchi E, Minicuci N, et al. Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study. Aging Clin Exp Res 2005; 17(1): 54-561.
15. Rimmer E, Stave C, Sganga A, O'Connell B. Implications of the Facing Dementia Survey for policy makers and third-party organisations across Europe. Int J Clin Pract Suppl 2005(146): 34-38.
16. Rimmer E, Wojciechowska M, Stave C, Sganga A, O'Connell B. Implications of the Facing Dementia Survey for the general population, patients and caregivers across Europe. Int J Clin Pract Suppl 2005(146): 17-24.
17. Wilkinson D, Sganga A, Stave C, O'Connell B. Implications of the Facing Dementia Survey for health care professionals across Europe. Int J Clin Pract Suppl 2005(146): 27-31.
18. Klein P. Le rapport des français et des européens à l'ordonnance ety aux médicaments. Paris: IPSOS-Sante; Caisse Nationale d'Assurance Maladie; 2005 10-18-2005.